Bis-arylidene oxindoles for colorectal cancer nanotherapy
Bioorganic Chemistry · 2024
DOI: 10.1016/j.bioorg.2024.107294 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Tithi Bhattacharyya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oils, Lipid Science & Technology, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India; Academy of Scientific and Innova…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colorectal Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, University Grants Commission, Department of Science and Technology.
Abstract (Originalsprache)
Oxindoles are potent anti-cancer agents and are also used against microbial and fungal infections and for treating neurodegenerative diseases. These oxindoles are earlier established as estrogen receptor (ER)-targeted agents for killing ER (+) cancer cells. Our previously developed bis-arylidene oxindole, Oxifen (OXF) exhibits effective targeting towards ER (+) cancer cells which has a structural resemblance with tamoxifen. Herein, we have designed and synthesized few structural analogues of OXF such as BPYOX, ACPOX and ACPOXF to examine its cytotoxicity in different cancer as well as non-cancer cell lines and its potential to form self- aggregates in aqueous solution. Among these series of molecules, ACPOXF showed maximum toxicity in colorectal cancer cell line which are ER (-) but it also kills non-cancer cell line HEK-293, thereby reducing its cancer cell selectivity. Incidentally, ACPOXF exhibits self-aggregation, without the help of a co-lipid with nanometric size in aqueous solution. ACPOXF self-aggregate was co-formulated with glucocorticoid receptor (GR) synthetic ligand, dexamethasone (Dex) (called, ACPOXF-Dex aggregate) which could selectively kill ER (-) colorectal cancer cells and also could increase survivability of colon-tumour bearing mice. ACPOXF-Dex induced ROS up-regulation followed by apoptosis through expression of caspase-3. Further, we observed upregulation of antiproliferative factor, p53 and epithelial-to-mesenchymal (EMT) reversal marker E-cadherin in tumour mass. In conclusion, a typical structural modification in ER-targeting Oxifen moiety resulted in its self-aggregation that enabled it to carry a GR-ligand, thus broadening its selective antitumor property especially as colon cancer therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oils, Lipid Science & Technology, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India; Academy of Scientific and Innovative Research (AcSIR), CSIR-HRDC Campus, Ghaziabad 201002, India. Elec…
- Department of Chemistry, University of Calcutta, Kolkata 700073, India. Electronic address: mrs.tanu123@gmail.com.
- Department of Chemistry, University of Calcutta, Kolkata 700073, India. Electronic address: dasdebojyoti39@gmail.com.
- Department of Chemistry, University of Calcutta, Kolkata 700073, India. Electronic address: ssachem@caluniv.ac.in.
Förderung
- Council of Scientific and Industrial Research, India
- University Grants Commission
- Department of Science and Technology
- Science and Engineering Research Board
Zitieren
APA
Bhattacharyya, T., Mishra, T., Das, D., Adhikari, S. S., & Banerjee, R. (2024). Bis-arylidene oxindoles for colorectal cancer nanotherapy. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.107294
Vancouver
Bhattacharyya T, Mishra T, Das D, Adhikari SS, Banerjee R. Bis-arylidene oxindoles for colorectal cancer nanotherapy. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2024.107294
BibTeX
@article{Bhattacharyya2024,
author = {Bhattacharyya, Tithi and Mishra, Tanushree and Das, Debojyoti and Adhikari, Susanta S and Banerjee, Rajkumar},
title = {Bis-arylidene oxindoles for colorectal cancer nanotherapy},
journal = {Bioorganic Chemistry},
year = {2024},
doi = {10.1016/j.bioorg.2024.107294}
}
EUVIMED